1
|
Konduktorova VV, Luchinskaya NN, Belyavsky AV. Expression of the Germes Germ Plasm Gene in Follicular Cells of X. laevis Oocytes. Russ J Dev Biol 2022. [DOI: 10.1134/s1062360422050034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
|
2
|
A novel strategy for production of liraglutide precursor peptide and development of a new long-acting incretin mimic. PLoS One 2022; 17:e0266833. [PMID: 35500009 PMCID: PMC9060347 DOI: 10.1371/journal.pone.0266833] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2021] [Accepted: 03/29/2022] [Indexed: 11/27/2022] Open
Abstract
Nowadays, a small number of incretin mimics are used to treat type 2 diabetes mellitus (T2DM) due to their longer half-life. The present study aimed to introduce a novel method for producing the liraglutide precursor peptide (LPP) and developing a potentially new incretin mimic. Here, human αB-crystallin (αB-Cry) was ligated to the LPP at the gene level, and the gene construct was expressed in Escherichia coli with a relatively good efficiency. The hybrid protein (αB-lir) was then purified by a precipitation method followed by anion exchange chromatography. After that, the peptide was released from the carrier protein by a chemical cleavage method yielding about 70%. The LPP was then purified by gel filtration chromatography, and HPLC estimated its purity to be about 98%. Also, the molecular mass of the purified peptide was finally confirmed by mass spectroscopy analysis. Assessment of the secondary structures suggested a dominant α-helical structure for the LPP and a β-sheet rich structure for the hybrid protein. The subcutaneous injection of the LPP and the αB-lir hybrid protein significantly reduced the blood sugar levels in healthy and diabetic mice and stimulated insulin secretion. Also, the hybrid protein exerts its bioactivities more effectively than the LPP over a relatively longer period of time. The results of this study suggested a novel method for the easy and cost-effective production of the LPP and introduced a new long-acting incretin mimic that can be potentially used for the treatment of T2DM patients.
Collapse
|
3
|
Kim YS, Lee HJ, Park SH, Kim YC, Ahn J. Expression and purification of soluble and active human enterokinase light chain in Escherichia coli. ACTA ACUST UNITED AC 2021; 30:e00626. [PMID: 34026576 PMCID: PMC8134707 DOI: 10.1016/j.btre.2021.e00626] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2020] [Revised: 04/29/2021] [Accepted: 05/01/2021] [Indexed: 11/30/2022]
Abstract
Recombinant production of soluble, active enterokinase (EK) is challenging. Maltose binding protein-fusion improves EK solubility but reduces activity. GroEL/ES and Erv2/PDI induces correct refolding and improves EK activity. Replacing free cysteine with serine dramatically improves EK activity.
Human enterokinase light chain (hEKL) specifically cleaves the sequence (Asp)4-Lys↓X (D4K), making this a frequently used enzyme for site-specific cleavage of recombinant fusion proteins. However, hEKL production from Escherichia coli is limited due to intramolecular disulphide bonds. Here, we present strategies to obtain soluble and active hEKL from E. coli by expressing the hEKL variant C112S fused with maltose-binding protein (MBP) through D4K and molecular chaperons including GroEL/ES. The fusion protein self-cleaved in vivo, thereby removing the MBP in the E. coli cells. Thus, the self-cleaved hEKL variant was released into the culture medium. One-step purification using HisTrap™ chromatography purified the hEKL variant exhibiting an enzymatic activity of 3.1 × 103 U/mL (9.934 × 105 U/mg). The approaches presented here greatly simplify the purification of hEKL from E. coli without requiring refolding processes.
Collapse
Affiliation(s)
- Young Su Kim
- Department of Chemical and Biomolecular Engineering, KAIST, Daejeon 34141, Republic of Korea.,Biotechnology Process Engineering Center, KRIBB, Cheongju 28116, Republic of Korea
| | - Hye-Jeong Lee
- Biotechnology Process Engineering Center, KRIBB, Cheongju 28116, Republic of Korea
| | - Sang-Hyun Park
- Biotechnology Process Engineering Center, KRIBB, Cheongju 28116, Republic of Korea.,Department of Bioprocess Engineering, KRIBB School of Biotechnology, Korea University of Science and Technology (UST), 217 Gajeong-ro, Yuseong-gu, Daejeon 34113, Republic of Korea
| | - Yeu-Chun Kim
- Department of Chemical and Biomolecular Engineering, KAIST, Daejeon 34141, Republic of Korea
| | - Jungoh Ahn
- Biotechnology Process Engineering Center, KRIBB, Cheongju 28116, Republic of Korea.,Department of Bioprocess Engineering, KRIBB School of Biotechnology, Korea University of Science and Technology (UST), 217 Gajeong-ro, Yuseong-gu, Daejeon 34113, Republic of Korea
| |
Collapse
|
4
|
Li Z, Cai Z, Fu W, Liu Y, Tian C, Wang H, Fu T, Wu Z, Wu D, Jin Y, Cheng Z, Terada N, Liu L, Wu W, Jin S, Bai F. High-efficiency protein delivery into transfection-recalcitrant cell types. Biotechnol Bioeng 2019; 117:816-831. [PMID: 31814110 DOI: 10.1002/bit.27245] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2019] [Revised: 11/14/2019] [Accepted: 11/30/2019] [Indexed: 12/15/2022]
Abstract
Intracellular delivery of functional proteins is of great interest for basic biological research as well as for clinical applications. Transfection is the most commonly used method, however, it is not applicable to large-scale manipulation and inefficient in important cell types implicated in biomedical applications, such as epithelial, immune and pluripotent stem cells. In this study, we explored a bacterial type III secretion system (Bac-T3SS)-mediated proteofection method to overcome these limitations. An attenuated Pseudomonas aeruginosa vector was constructed, which has features of low toxicity, high T3SS activity, and self-limiting growth. Compared to the method of transfection, the Bac-T3SS showed significantly higher efficiencies of Cre recombinase translocation and target site recombination for hard-to-transfect human cell lines. Furthermore, through the delivery of β-lactamase in live animals, we demonstrated the feasibility and biosafety of in vivo application of the Bac-T3SS. This study provided an efficient and low-cost proteofection strategy for laboratory use as well as for application in large-scale cell manipulations.
Collapse
Affiliation(s)
- Zhenpeng Li
- State Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Molecular Microbiology and Technology of the Ministry of Education, College of Life Sciences, Nankai University, Tianjin, China
| | - Zeqiong Cai
- State Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Molecular Microbiology and Technology of the Ministry of Education, College of Life Sciences, Nankai University, Tianjin, China
| | - Weixin Fu
- State Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Molecular Microbiology and Technology of the Ministry of Education, College of Life Sciences, Nankai University, Tianjin, China
| | - Ying Liu
- State Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Molecular Microbiology and Technology of the Ministry of Education, College of Life Sciences, Nankai University, Tianjin, China
| | - Chenglei Tian
- State Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Molecular Microbiology and Technology of the Ministry of Education, College of Life Sciences, Nankai University, Tianjin, China
| | - He Wang
- State Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Molecular Microbiology and Technology of the Ministry of Education, College of Life Sciences, Nankai University, Tianjin, China
| | - Tongtong Fu
- State Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Molecular Microbiology and Technology of the Ministry of Education, College of Life Sciences, Nankai University, Tianjin, China
| | - Zhenzhou Wu
- State Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Molecular Microbiology and Technology of the Ministry of Education, College of Life Sciences, Nankai University, Tianjin, China
| | - Donghai Wu
- Key Laboratory of Regenerative Biology, Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China
| | - Yongxin Jin
- State Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Molecular Microbiology and Technology of the Ministry of Education, College of Life Sciences, Nankai University, Tianjin, China
| | - Zhihui Cheng
- State Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Molecular Microbiology and Technology of the Ministry of Education, College of Life Sciences, Nankai University, Tianjin, China
| | - Naohiro Terada
- Department of Pathology, Immunology and Laboratory Medicine, University of Florida, Gainesville, Florida
| | - Lin Liu
- State Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Molecular Microbiology and Technology of the Ministry of Education, College of Life Sciences, Nankai University, Tianjin, China
| | - Weihui Wu
- State Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Molecular Microbiology and Technology of the Ministry of Education, College of Life Sciences, Nankai University, Tianjin, China
| | - Shouguang Jin
- Department of Molecular Genetics and Microbiology, University of Florida, Gainesville, Florida
| | - Fang Bai
- State Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Molecular Microbiology and Technology of the Ministry of Education, College of Life Sciences, Nankai University, Tianjin, China
| |
Collapse
|
5
|
Mi Y, Gao Y, Fan D, Duan Z, Fu R, Liang L, Xue W, Wang S. Stability improvement of human collagen α1(I) chain using insulin as a fusion partner. Chin J Chem Eng 2018. [DOI: 10.1016/j.cjche.2018.04.008] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
6
|
Wang J, Yu H, Tian S, Yang H, Wang J, Zhu W. Recombinant expression insulin-like growth factor 1 in Bacillus subtilis using a low-cost heat-purification technology. Process Biochem 2017. [DOI: 10.1016/j.procbio.2017.08.015] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
7
|
Deng L, Xue X, Shen C, Song X, Wang C, Wang N. Insulin chains as efficient fusion tags for prokaryotic expression of short peptides. Protein Expr Purif 2017; 138:46-55. [DOI: 10.1016/j.pep.2017.06.019] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2017] [Revised: 05/22/2017] [Accepted: 06/30/2017] [Indexed: 01/02/2023]
|
8
|
Kodaganti BP, Mukunda P, Dakshinamurthy P, Manjunath Y, Shenoy BR, Kamanagowda V, Natarajan B, Maliwalave A, Unnikrishnan D, Murugesan S, Halan V, Ghosh M, Maity S. Microbial expression of Exendin-4 analog and its efficacy in mice model. Biologicals 2017; 48:82-91. [PMID: 28554726 DOI: 10.1016/j.biologicals.2017.05.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2016] [Revised: 05/09/2017] [Accepted: 05/16/2017] [Indexed: 02/06/2023] Open
Abstract
Exendin-4 is a GLP 1 agonist incretin-mimetic peptide hormone comprising 39 amino acids. Exenatide (Byetta®) is a chemically synthesized version of Exendin-4 with an additional C-terminal amidation. Exenatide acts as a GLP-1 receptor agonist. This paper illustrates the method adopted for cloning, fermentation and purification of recombinant Exendin-4 analog expressed in Escherichia coli. The biologically expressed analog was extensively characterized using different orthogonal methods to confirm their biological activity and physicochemical properties. It was observed that the expressed analog showed comparable functional properties as that of Byetta® irrespective of their modes of development. Further, in vivo efficacy of the recombinant Exendin-4 analog was studied in Oral Glucose Tolerance Test (OGTT) in mice models. Byetta® and Exendin-4 analog treated groups showed comparable glucose lowering activity in the OGTT model.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | - Sunit Maity
- Theramyt Novobiologics Pvt Ltd, Bangalore, India; Zumutor Biologics, Bangalore, India.
| |
Collapse
|
9
|
Basso AMM, Pelegrini PB, Mulinari F, Costa MC, Viana AB, Silva LP, Grossi-de-Sa MF. Recombinant glucagon: a differential biological activity. AMB Express 2015; 5:20. [PMID: 25852997 PMCID: PMC4385203 DOI: 10.1186/s13568-015-0099-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2014] [Accepted: 01/22/2015] [Indexed: 11/13/2022] Open
Abstract
In Brazil, there is a growing demand for specialised pharmaceuticals, and the high cost of their importation results in increasing costs, reaching US$ 1.34 billion in 2012 and US$ 1.61 billion in 2013. Worldwide expenses related to drugs could reach US$ 1.3 trillion in 2018, especially due to new treatments for hepatitis C and cancer. Specialised or high-cost pharmaceutical drugs used for the treatment of viral hepatitis, multiple sclerosis, HIV and diabetes are distributed free of charge by the Brazilian government. The glucagon peptide was included in this group of high-cost biopharmaceuticals in 2008. Although its main application is the treatment of hypoglycaemia in diabetic patients, it can also be used with patients in an alcoholic coma, for those patients with biliary tract pain, and as a bronchodilator. Therefore, in order to reduce biopharmaceutical production costs, the Brazilian government passed laws focusing on the development and increase of a National Pharmaceutical Industrial Centre, including the demand for the national production of glucagon. For that reason and given the importance and high cost of recombinant glucagon, the purpose of this study was to develop methods to improve production, purification and performance of the biological activity of recombinant glucagon. Glucagon was recombined into a plasmid vector containing a Glutathione S-transferase tag, and the peptide was expressed in a heterologous Escherichia coli system. After purification procedures and molecular analyses, the biological activity of this recombinant glucagon was examined using in vivo assays and showed a highly significant (p < 0.00001) and prolonged effect on glucose levels when compared with the standard glucagon. The experimental procedure described here facilitates the high level production of recombinant glucagon with an extended biological activity.
Collapse
Affiliation(s)
- Angelina M M Basso
- />Department of Molecular Pathology, University of Brasilia, Brasilia, DF Brazil
- />Laboratory of Plant-Pest Interaction, Embrapa – Genetic Resources and Biotechnology, Brasília, DF Brazil
| | - Patrícia B Pelegrini
- />Laboratory of Plant-Pest Interaction, Embrapa – Genetic Resources and Biotechnology, Brasília, DF Brazil
| | - Fernanda Mulinari
- />Laboratory of Plant-Pest Interaction, Embrapa – Genetic Resources and Biotechnology, Brasília, DF Brazil
- />Pioneer Union for Social Insertion – UPIS, Planaltina, DF Brazil
| | - Michelle C Costa
- />Laboratory of Plant-Pest Interaction, Embrapa – Genetic Resources and Biotechnology, Brasília, DF Brazil
| | - Antonio B Viana
- />Laboratory of Plant-Pest Interaction, Embrapa – Genetic Resources and Biotechnology, Brasília, DF Brazil
- />Catholic University of Brasilia, Brasilia, DF Brazil
| | - Luciano P Silva
- />Laboratory of Mass Spectrometry, Embrapa – Genetic Resources and Biotechnology, Brasília, DF Brazil
| | - Maria Fatima Grossi-de-Sa
- />Laboratory of Plant-Pest Interaction, Embrapa – Genetic Resources and Biotechnology, Brasília, DF Brazil
- />Catholic University of Brasilia, Brasilia, DF Brazil
| |
Collapse
|